← Leaderboards
Seth P. Lerner
Baylor College Of Medicine
$377,294
Attributed
$1,110,775
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $228.9K · FY2008–16$250K$187.5K$125K$62.5K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$1,110,775 · 6
By mechanism
P50$1,100,221 · 2
M01$10,554 · 4
Top collaborators
- Ashish M Kamat5 shared
- Xifeng Wu5 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Timothy C Thompson$13,464,867
- C Kent Osborne$24,386,086
- Bert W O'Malley$52,747,816
- Peter T Scardino$5,501,749
- Steffi Oesterreich$10,632,097
Others in their field
Top investigators on “Staging”
- Richard K. Wilson · Washington University$281,315,172
- David Heimbrook · Leidos Biomedical Research, Inc.$277,888,083
- Chanza Baytop · Westat, Inc.$271,217,917
- Francis L Halzen · University Of Wisconsin-Madison$208,995,120
- Demian A Bailey · Oregon State University$199,999,984
- Clare E Reimers · Gordon Research Conferences$199,999,984
Research focus
StagingCohortTumorSiteMalignant Neoplasm Of Urinary BladderMalignant NeoplasmsResponseToxic EffectClinical TrialsBiogenesisEpidemiologyEpidemiologic DataCancer EtiologyCancer PrognosisEtiologyEventCaucasiansCase-Control StudiesCase ControlClinical DataDesignChemopreventionEnrollmentAccounting
Grant awards (9)
Role of MicroRNA in Bladder Cancer Risk and Outcome: A Genome-Wide analysis$217,966
P50 · FY2016 · CA
Role of MicroRNA in Bladder Cancer Risk and Outcome: A Genome-Wide analysis$228,909
P50 · FY2015 · CA
Role of MicroRNA in Bladder Cancer Risk and Outcome: A Genome-Wide analysis$225,831
P50 · FY2014 · CA
Role of MicroRNA in Bladder Cancer Risk and Outcome: A Genome-Wide analysis$224,314
P50 · FY2013 · CA
Role of MicroRNA in Bladder Cancer Risk and Outcome: A Genome-Wide analysis$203,201
P50 · FY2012 · CA
CLINICAL TRIAL: PHASE II STUDY OF TAMOXIFEN FOR PROGRESSIVE TRANSITIONAL CELL C$1,979
M01 · FY2011 · RR · contact PI
CLINICAL TRIAL: PHASE II STUDY OF TAMOXIFEN FOR PROGRESSIVE TRANSITIONAL CELL CA$4,197
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: PHASE II STUDY OF TAMOXIFEN FOR PROGRESSIVE TRANSITIONAL CELL CA$2,370
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE II STUDY OF TAMOXIFEN FOR PROGRESSIVE TRANSITIONAL CELL CA$2,008
M01 · FY2008 · RR · contact PI